iBio (IBIO) Cash & Equivalents (2010 - 2026)

iBio (IBIO) has reported Cash & Equivalents for 17 consecutive years, with $47.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 852.62% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $47.6 million (up 852.62% YoY), while the FY2025 annual figure was $8.6 million, down 39.61% from the prior year.
• Cash & Equivalents improved to $47.6 million in Q1 2026 per IBIO's latest filing, from $28.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $47.6 million in Q1 2026 and bottomed at $1.5 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $14.2 million across 5 years, with a median of $8.6 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 90.57% — and 2026, when it surged 852.62%.
• iBio's Cash & Equivalents stood at $3.7 million in 2022, then slipped by 24.57% to $2.8 million in 2023, then surged by 151.61% to $7.0 million in 2024, then surged by 308.72% to $28.7 million in 2025, then soared by 66.12% to $47.6 million in 2026.
• Business Quant data shows IBIO's Cash & Equivalents at $47.6 million in Q1 2026, $28.7 million in Q4 2025, and $28.1 million in Q3 2025.